Element Biosciences

Element Biosciences

Biotechnology firm specializing in DNA sequencing

About Element Biosciences

Simplify's Rating
Why Element Biosciences is rated
B+
Rated B on Competitive Edge
Rated A on Growth Potential
Rated B on Differentiation

Industries

Biotechnology

Healthcare

Company Size

201-500

Company Stage

Series D

Total Funding

$678M

Headquarters

San Diego, California

Founded

2017

Overview

Element Biosciences focuses on next-generation sequencing (NGS) technology, offering the AVITI System, a compact benchtop device that provides high-quality sequencing at a low cost of $1 per million reads. This system is designed for accuracy and efficiency, catering to clients like academic researchers and pharmaceutical companies. Element Biosciences stands out by forming partnerships with other biotech firms, such as QIAGEN, to deliver complete NGS workflows, and by running the 2023 AVITI for All Grant program, which offers free sequencing for various applications. The company's goal is to make high-quality sequencing accessible and affordable for a diverse range of users.

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for personalized medicine boosts need for Element's affordable sequencing.
  • Spatial multiomics trend creates new opportunities for Element's product expansion.
  • Decentralization of sequencing supports market for Element's compact AVITI System.

What critics are saying

  • Competition from established players like Illumina may pressure Element's market share.
  • Rapid technological advancements require continuous innovation, straining Element's resources.
  • High investor expectations from $680M funding could pressure Element for rapid growth.

What makes Element Biosciences unique

  • Element Biosciences offers the AVITI System, a cost-effective DNA sequencing platform.
  • The company's technology improves signal-to-noise ratio, enhancing sequencing data quality.
  • Element's partnerships, like with QIAGEN, provide comprehensive NGS workflows.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$678M

Above

Industry Average

Funded Over

4 Rounds

Series D funding is typically for companies that are already well-established but need more funding to continue their growth. This round is often used to stabilize the company or prepare for an IPO.
Series D Funding Comparison
Above Average

Industry standards

$77M
$70M
Twilio
$80M
Handshake
$100M
Affirm
$277M
Element Biosciences

Benefits

100% company-paid medical, dental, & vision coverage

Flexible spending & health savings accounts

Premier mental health care

401(k) with immediately vested 4% company match

Company-paid Life and AD&D insurance

Stock option grants

Flexible time off

10 paid annual holidays

8-weeks paid parental leave

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

0%

2 year growth

1%
iGrow News
Apr 11th, 2025
Daicel Arbor Biosciences Launches 2025 AVITI for Agrigenomics Grant

Daicel Arbor Biosciences and Element Biosciences launch the 2025 AVITI for Agrigenomics Accelerator Grant.

MWBN
Apr 10th, 2025
Accelerating agrigenomics: Daicel Arbor Biosciences and Element Biosciences announce new grant opportunity

ANN ARBOR, Mich., April 10, 2025 /PRNewswire/ - Daicel Arbor Biosciences, a company that offers tools and services to accelerate genomics and synthetic biology research, in collaboration with Element Biosciences, a life sciences company democratizing access to advanced biological tools,...

Securities.io
Feb 24th, 2025
Illumina (Ilmn): Building The Picks And Shovels Of The Genomic Age

Genome Sequencing Cost CurveFor most of the history of medicine, doctors have been limited to observing symptoms and trying to alleviate them. This has been especially true for non-infectious diseases stemming from dysfunction in the body, including genetic diseases.With the discovery of DNA structure and function, awarded the 1962 Nobel Prize in Medicine , we started to have a better understanding of how the biological system truly works. PCR technology, awarded the 1993 Nobel Prize in Medicine , would open new ways to analyze it.This further expanded when full genomes started to be sequenced. The first human genome was sequenced in 2003 after 13 years of hard work, for a cost of $3B. Quickly, full-genome sequencing started to become cheaper and cheaper. By 2007, it would cost “only” $1M to sequence a full genome

HR Tech Wire
Feb 20th, 2025
Element Unveils AVITI24(TM) Innovation Roadmap Ahead of the Advances in Genome Biology and Technology (AGBT) 2025 Annual Meeting

Element Biosciences, Inc., a company democratizing access to advanced life science solutions, today announced the Innovation Roadmap for AVITI24,(TM) the world's first natively paired spatial multiomic solution.

Labiotech
Jan 30th, 2025
Seven Genomics Startups To Look Out For

Newsletter Signup - Under Article / In Page"*" indicates required fields Precision medicine is a kind of treatment strategy that is tailored to individual patients, most of which is dependent on their genetic makeup. Genomics, which deals with the mapping of genomes, is a booming industry that aims to advance precision medicine to address a host of diseases. You may have heard of the big names in the business, like Illumina, Oxford Nanopore Technology, and Thermo Fisher Scientific. But there are a number of genomics startups that have sprouted up in the past decade or so to strengthen their sequencing technologies to aid in disease prevention and treatment. Here are seven genome sequencing startups that are making their mark in the industry.Element BiosciencesFounded in 2017, Element Biosciences shot to fame fairly quickly after the launch of its lab services. Its benchtop sequencing instrument AVITI has a dual flow cell layout and individually addressable lanes and you can perform two parallel runs and operate each side independently. Its alternative model, AVITI LT, is a lower-cost, lower-throughput solution that brings next-generation sequencing (NGS) to more labs.The core components of Element’s sequencing tool include an Avidite base chemistry, which circularizes, copies, and rolls each strand into tightly bound polonies – tiny clusters of identical DNA molecules – without the use of PCR and fluorescent avidites that bind to each polony creating ultrastable complexes. It also employs rolling circle amplification, which is a process that uses a circular DNA template to create long single-stranded DNA molecules to avoid errors such as index hopping – when sequencing reads are incorrectly assigned to the wrong sample in a pool. Its sought-after technology is called LoopSeq, which prepares libraries for long-read sequencing on the short-read Element AVITI System

Recently Posted Jobs

Sign up to get curated job recommendations

Senior Sales Representative

$154k - $164k/yr

Boston, MA, USA

Senior Product Manager - Software/AI

$145k - $185k/yr

San Diego, CA, USA

Facilities Engineer

$97k - $118k/yr

San Diego, CA, USA

See All Jobs

Element Biosciences is Hiring for 13 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Element Biosciences's jobs every few hours, so check again soon! Browse all jobs →

Senior Product Manager - Software/AI

$145k - $185k/yr

San Diego, CA, USA

Facilities Engineer

$97k - $118k/yr

San Diego, CA, USA

See All Jobs

Element Biosciences is Hiring for 13 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Element Biosciences's jobs every few hours, so check again soon! Browse all jobs →